Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels  by Toth, Peter P. et al.
lable at ScienceDirect
Atherosclerosis 237 (2014) 790e797Contents lists avaiAtherosclerosis
journal homepage: www.elsevier .com/locate/atherosclerosisClinical and economic outcomes in a real-world population of patients
with elevated triglyceride levels
Peter P. Toth a, b, Michael Grabner c, *, Nadia Ramey d, e, Keiko Higuchi f
a CGH Medical Center, Sterling, IL, USA
b Johns Hopkins University School of Medicine, Baltimore, MD, USA
c HealthCore, Inc., Wilmington, DE, USA
d Rutgers University, School of Health Related Professions, Newark, NJ, USA
e ESAC Inc., Rockville, MD, USA
f Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAa r t i c l e i n f o
Article history:
Received 11 August 2014
Received in revised form
28 September 2014
Accepted 29 September 2014
Available online 17 October 2014
Keywords:
Hypertriglyceridemia
Health outcomes
Health services research
Health care costs
Treatment patterns
Pancreatitis
Fibrate
StatinAbbreviations: CVD, cardiovascular disease; HTG
odds ratio; TG, triglyceride.
* Corresponding author. HealthCore, Inc., 800 De
Wilmington, DE 19801-1366, USA.
E-mail addresses: Peter.Toth@cghmc.com (P.P. Toth
(M. Grabner), nadia.ramey@gmail.com (N. Ramey),
(K. Higuchi).
http://dx.doi.org/10.1016/j.atherosclerosis.2014.09.029
0021-9150/© 2014 The Authors. Published by Elsevier
nd/3.0/).a b s t r a c t
Objective: This study investigated real-world treatment patterns, healthcare utilization, and costs of
hypertriglyceridemia in a large commercially insured United States population. Methods: This obser-
vational claims study was conducted among adult patients with TG > 500 mg/dL between 01/01/2007
and 04/30/2013. Patients were stratiﬁed into mutually exclusive cohorts based on their ﬁrst available TG
measurement (index date): TG  1500 (Cohort A); 750  TG < 1500 (Cohort B), and 500 < TG < 750
(Cohort C). Study inclusion required 12 months of eligibility pre- (baseline) and posteindex date
(follow-up). Patient characteristics and outcomes were assessed descriptively. Costs associated with
acute pancreatitis episodes were estimated using a Generalized Linear Model regression. Results: We
identiﬁed a total of 1964 patients in Cohort A, 7432 in Cohort B, and 17,500 in Cohort C. Patients were
young (mean age 46e48) and mostly male (75%e80%). Treatment switching and augmentation occurred
rarely, and almost 50% of patients discontinued their initial treatment. At baseline, healthcare utilization
and costs were highest in Cohort A (mean all-cause medical and pharmacy costs, $8850). At follow-up,
the number of patients with dyslipidemia-related ofﬁce and pharmacy claims and related costs almost
doubled across the cohorts. Mean all-cause costs/patient in Cohort A at follow-up were $12,642, of which
$3730 were dyslipidemia-related. Acute pancreatitis episodes were associated with >300% increase in
total all-cause costs in Cohort A. Conclusions: These results suggest that severe hypertriglyceridemia is
undertreated and healthcare utilization and costs scale with magnitude of TG elevation. Patients with
more severe hypertriglyceridemia received greater medical and pharmacy services. Managing severe
hypertriglyceridemia more aggressively and preventing acute pancreatitis may generate cost savings.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hypertriglyceridemia (HTG) is prevalent among a third of the
adult population in the United States (US) [17]. HTG is deﬁned as
fasting blood plasma triglyceride (TG) levels 150 mg/dL by the
National Cholesterol Education Program Adult Treatment Panel III, hypertriglyceridemia; OR,
laware Avenue, Fifth Floor,
), mgrabner@healthcore.com
keiko.higuchi@novartis.com
Ireland Ltd. This is an open access[15,16]. The prevalence of severe HTG (TG > 500 mg/dL) is
approximately 2% among adult Americans [27].
HTG is a deﬁning feature of the metabolic syndrome and is
commonly encountered in patients with diabetes mellitus (DM)
and chronic kidney disease [22]. Severe HTG is multifactorial and a
large number of genetic polymorphisms are etiologic for this
metabolic phenotype. Chylomicronemia (type I dyslipoproteine-
mia), familial hypertriglyceridemia (type IV dyslipoproteinemia),
and familial mixed hypertriglyceridemia (type V dyslipoproteine-
mia) arise from derangements in the metabolism of chylomicrons,
very low-density lipoproteins (VLDL), or a combination of chylo-
microns and VLDL, respectively [7,14].
Some studies suggest that HTG is associated with increased risk
for coronary heart disease and its complications [2,21]. In thearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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teins (incompletely digested chylomicrons and VLDLs) are
dramatically increased. Recent analyses from prospective epide-
miologic cohorts strongly suggest that lipoprotein remnants are
atherogenic [10,13,24] and are associated with increased risk of
stroke [9] and coronary events [23]. One of the most clinically
important complications of severe HTG is acute pancreatitis, an
extremely painful and life-threatening condition that increases
risk for chronic epigastric pain, DM, and pancreatic digestive
enzyme deﬁciency [3,12,25,26]. Approximately 10% of cases of
acute pancreatitis and 56% of cases of gestational pancreatitis occur
in patients with severe HTG [1]. Other complications associated
with severe HTG include lipemia retinalis, sensory neuropathy,
chronic abdominal pain, tubero-eruptive xanthomas, and
hepatosplenomegaly.
Treatment approaches for the management of severe HTG
include aggressive restriction of dietary saturated fat intake,
enriching the diet with medium chain fatty acid, relieving insulin
resistance which may be contributory (weight loss, exercise, and
smoking cessation), and the use of such drugs as statins, ﬁbrates,
niacin, and omega-3 ﬁsh oils [8,11,15,16,19,28]. The ﬁbrates and ﬁsh
oils can be especially helpful since they not only reduce hepatic
VLDL production and secretion, but also activate lipoprotein lipase.
However, challenges remain in identifying individuals at high risk
for development of severe HTG complications, especially acute
pancreatitis [5].
Currently, real-world data on the clinical and demographic
characteristics, healthcare utilization patterns and costs associated
with severe HTG are limited, and as a result this group of patients is
inadequately characterized. The goal of this retrospective claims
study was to examine the treatment patterns, clinical outcomes,
healthcare utilization, and costs associated with severe HTG. In
addition, we examined the incidence and costs associated with
acute pancreatitis episodes.2. Methods
2.1. Study design and population
The data for this retrospective cohort study consisted of medical
and pharmacy administrative claims and electronic laboratory re-
sults taken from the HealthCore Integrated Research Database
(HIRDSM) for the period 01/01/2006 through 04/30/2013. The HIRD
is a repository of longitudinal claims data from 14 geographically
dispersed US commercial health plans with approximately 36
million lives. Patients with severe HTGe deﬁned as TG> 500mg/dL
for the purposes of this study e between 01/01/2007 and 04/30/
2012 were stratiﬁed into three mutually exclusive cohorts based on
their ﬁrst available TG measurement (index date): Cohort A
(TG  1500); Cohort B (750  TG < 1500) and Cohort C
(500 < TG < 750 mg/dL). The index therapy for each included pa-
tient was determined as the closest relevant pharmacy ﬁll (for ﬁsh
oil, ﬁbrates, niacin, statins or other lipid lowering agents) relative to
the index date, within an allowable time period between the index
date (inclusive) and index dateþ120 days. Index therapy was set to
missing when no relevant pharmacy ﬁlls were observed.
In this non-experimental study, all materials were handled in
strict compliance with the Health Insurance Portability and
Accountability Act (HIPAA). Data were kept anonymous throughout
and patient conﬁdentially was safeguarded; researchers only
accessed a limited data set devoid of any individual patient iden-
tiﬁers. The study was performed under the Research Exception
provisions of the Privacy Rule, 45 CFR 164.514(e), which exempted
it from Investigational Review Board (IRB) approval.2.2. Inclusion/exclusion criteria
To be included in the study, patients were required to be at least
18 years of age and to have at least one result for an electronic
laboratory claim with an elevated triglyceride level of at least
500 mg/dL. Inclusion also required 12 months (360 days)
continuous medical and pharmacy enrollment before the index
date (baseline period) and 12 months (360 days) continuous
medical and pharmacy enrollment (follow-up period) after the
index therapy ﬁll (or after index date if no index therapy ﬁll was
observed). Patients who had at least one claim for pregnancy dur-
ing the baseline or follow-up period were excluded as pregnancy
could temporarily increase TG levels. This study did not include any
patients receiving Medicare coverage.
2.3. Patient characteristics and outcome measures
2.3.1. Baseline only
Patient characteristics including age, gender, geographic loca-
tion and comorbidities were evaluated for the baseline period.
Mean baseline comorbidity scores were measured with the Quan-
Charlson comorbidity index [20].
2.3.2. Baseline and follow-up
Treatment patterns and the prevalence of conditions associated
with ICD-9-CM code 272.xx were assessed during the pre- and
posteindex periods. Medication utilization was evaluated around
index date (index date ±30 days) and again at 6-month follow-up
(index date þ150 days to index date þ 210 days). Physician spe-
cialty was assessed at the time of the index therapy ﬁll and during
follow-up. In a subgroup of TG-treatment naïve patients, we eval-
uated treatment discontinuation, switching, and augmentation, as
well as medication adherence using Proportion of Days Covered
(PDC). PDC was measured as the proportion of the sum of the
number of non-overlapping days with the index drug on-hand
divided by the number of days in the follow-up period.
Laboratory test results were assessed around index date and 12
months follow-up for TG levels, low density lipoprotein cholesterol,
high density lipoprotein cholesterol, total cholesterol, and HbA1c.
All-cause and disease-related healthcare resource utilization
and costs were evaluated both at baseline and during follow-up.
Disease-related utilization included all medical claims with an
ICD-9-CM code for dyslipidemia (272.xx) and all pharmacy claims
for TG-related medications including ﬁbrates, ﬁsh oils, and niacin.
Pancreatitis-related health care resource utilization and costs
included all medical claimswith an ICD-9-CM code of 577.0x and all
pharmacy claims for digestive enzymes. Costs were computed as
the total of plan paid plus patient paid amounts, and presented at
constant 2013 US dollars. All utilization and cost measures were
stratiﬁed by place of service (inpatient hospitalizations, stand-
alone emergency room visits, physician ofﬁce visits, and other
outpatient visits).
2.4. Statistical analysis
Descriptive analyses included means (standard deviations [SD])
and relative frequencies for continuous and categorical variables,
respectively. No comparisons were made across cohorts deﬁned by
TG levels. Within Cohort A, subgroups deﬁned by the presence or
absence of acute pancreatitis at follow-up were compared with
two-sample t-tests or non-parametric tests as appropriate for
continuous variables, and with chi-square tests or Fisher's exact
tests for categorical variables.
A multivariable logistic regression was performed on Cohort A
using acute pancreatitis over follow-up as the outcome and TG level
P.P. Toth et al. / Atherosclerosis 237 (2014) 790e797792on index date (in continuous form) as themain predictor of interest.
A second multivariable logistic regression was performed on the
combined sample (Cohort A plus B plus C) using acute pancreatitis
over follow-up as the outcome and TG level on index date (in cat-
egorical form) as the main predictor of interest. Lastly, a multivar-
iable generalized linear regression model (GLM) with a log link and
gamma distributionwas used to assess differences in the sum of all-
cause total medical and pharmacy costs across patients with and
without an acute pancreatitis episode during follow-up in Cohort A.
All multivariable models also included adjustments for baseline
demographic, clinical, and economic characteristics as applicable
(see Online Data Supplement for a complete list of covariates for
each model). All analyses were conducted in SAS 9.2 (SAS Institute
Inc., Cary, NC, 2008).
3. Results
3.1. Patient disposition
Overall, 53,627 patients with 1 laboratory claim for TGs with
values between >500 mg/dL and <15,000 were identiﬁed in the
study database. Following the application of inclusion re-
quirements, 1964 patients were identiﬁed with TG  1500 (Cohort
A), 7432 patients with TG levels between 750 and 1500 mg/dL
(Cohort B), and 17,500 patients with TG levels between 500 and
750 mg/dL (Cohort C), as shown in Fig. 1.
3.2. Demographic and clinical characteristics at baseline
Patients were young (mean age 46e48 years) and predominantly
male (75e80%) in each cohort. Theprevalenceof diabeteswas greatest
among patients in Cohort A (37.4%) followed by Cohort B (29.2%) and
Cohort C (24.3%). Slightly less than half of the patients in each of the
three cohorts had hypertension. The prevalence of mental health
disorders was consistent across the three cohorts at approximatelyFig. 1. Disposition of21%. Patients in Cohort A had a higher mean Quan-Charlson comor-
bidity index score versus the other cohorts, as shown in Table 1. The
prevalence of pancreatitis was four times greater among patients in
Cohort A compared to the other two cohorts (4.1% vs. <1%).
3.3. Diagnosis and treatment patterns
The majority of patients in each cohort were diagnosed with
“Other and unspeciﬁed hyperlipidemia” at both baseline and
follow-up. “Hypertriglyceridemia” was noted in <10% of patients at
baseline and ~20% of patients at follow-up (Tables 1 and 2).
Between 30 and 50% of TG-treatment-naïve patients did not initiate
any pharmacotherapy within 4 months of the index date. Among
thosewho did, approximately half received statins as their ﬁrst-line
therapy, with only 30% receiving ﬁbrates and approximately 8%
receiving ﬁsh oils. Almost half of the patients in each cohort dis-
continued their index therapy. Only about one-ﬁfth of the patients
in each cohort were medication adherent (PDC 80%). Approxi-
mately two-thirds of the patients in each cohort had a visit with a
primary care physician (PCP) during the initial care phase, while
less than 10% saw a specialist. Of those visiting a PCP during the
initial care phase, less than 20% had visits with a specialist during
follow-up. At 6 months of follow-up within the full sample, a
similarly high proportion of patients had no pharmacy claims for
TG medications (from 45% in Cohort A to 57% in Cohort C). Statins
and ﬁbrates remained the most often prescribed drugs. More than
20% of patients in Cohort A received two or more drug classes,
compared to 11% in Cohort C. (Fig. 2).
3.4. Laboratory results around index date versus 12-month follow-
up
Overall, laboratory values improved for patients in all three
cohorts during the 12-month follow-up period. The most notable
improvements were found in mean TG values, total cholesterol andstudy patients.
Table 1
Demographic and clinical characteristics of severe HTG patients at baseline.
Cohort A
TG1500
(n ¼ 1964)
Cohort B
750TG<1500
(n ¼ 7432)
Cohort C
500<TG<750
(n ¼ 17,500)
n % n % n %
Baseline demographics
Female, n (%) 383 (19.5) 1601 (21.5) 4436 (25.4)
Age, mean (SD) 46.4 (8.8) 47.8 (9.2) 48.3 (9.5)
Baseline comorbidities, n (%)
Quan-Charlson comorbidity
score, mean (SD)
0.89 (1.4) 0.82 (1. 5) 0.74 (1.3)
Diabetes 734 (37.4) 2169 (29.2) 4243 (24.3)
Renal disease 44 (2.2) 184 (2.5) 362 (2.1)
Liver disease 81 (4.1) 278 (3.7) 594 (3.4)
Hypertension 945 (48.1) 3401 (45.8) 7815 (44.7)
Obesity 159 (8.1) 446 (6.0) 1036 (5.9)
Alcohol abuse 166 (8.5) 541 (7.3) 1235 (7.1)
Hypothyroidism 123 (6.3) 512 (6.9) 1308 (7.5)
Mental health disorders 416 (21.2) 1593 (21.4) 3758 (21.5)
Pancreatitis (acute
or chronic)
81 (4.1) 69 (0.9) 105 (0.6)
Dyslipidemia diagnoses at baseline, n (%)
Hypercholesterolemia 378 (19.3) 1369 (18.4) 3206 (18.3)
Hypertriglyceridemia 161 (8.2) 422 (5.7) 746 (4.3)
Mixed hyperlipidemia 255 (13.0) 853 (11.5) 2004 (11.5)
Chylomicronemia 8 (0.4) 17 (0.2) 34 (0.2)
Other and unspeciﬁed
hyperlipidemia
674 (34.3) 2356 (31.7) 5372 (30.7)
Any dyslipidemia diagnosis 1105 (56.3) 3870 (52.1) 8823 (50.4)
TG ¼ triglyceride; SD ¼ standard deviation.
Table 2
Diagnoses and treatment patterns at follow-up.
Cohort A
TG1500
(n ¼ 1964)
Cohort B
750TG<1500
(n ¼ 7432)
Cohort C
500<TG<750
(n ¼ 17,500)
Dyslipidemia diagnoses at followeup, n (%)
Hypercholesterolemia 639 (32.5) 2352 (31.7) 5191 (29.7)
Hypertriglyceridemia 449 (22.9) 1134 (15.3) 2075 (11.9)
Mixed hyperlipidemia 542 (27.6) 1700 (22.9) 3826 (21.9)
Chylomicronemia 18 (0.9) 40 (0.5) 74 (0.4)
Other and unspeciﬁed
hyperlipidemia
1218 (62.0) 4238 (57.0) 9595 (54.8)
Any dyslipidemia
diagnosis
1768 (90.0) 6393 (86.0) 14,591 (83.4)
Treatment patternsa of
TG-treatment-naïve
patients, n (%)
1307 (66.5) 5678 (76.4) 14,393 (82.2)
No Rx claim 445 (34.0) 2325 (40.9) 7026 (48.8)
Monotherapy 744 (56.9) 3076 (54.2) 6949 (48.3)
Fish oil 59 (7.9) 236 (7.7) 508 (7.3)
Fibrates 261 (35.1) 1036 (33.7) 1895 (27.3)
Niacin 19 (2.6) 101 (3.3) 219 (3.2)
Statins 363 (48.8) 1518 (49.3) 3898 (56.1)
Others 42 (5.6) 185 (6.0) 429 (6.2)
Combination therapy 118 (90) 277 (4.9) 418 (2.9)
Patients discontinuing
index therapyb
162 (47.8) 636 (46.3) 1230 (46.9)
Patients switching from
their index therapy
10 (3.0) 33 (2.4) 80 (3.1)
Patients augmenting
their index therapy
21 (6.2) 87 (6.3) 100 (3.8)
Patients with PDC 80%c 71 (20.9) 268 (19.5) 486 (18.5)
Physician visit patterns
Physician Specialtyd, n (%)
PCP 1348 (68.6) 4887 (65.8) 10,618 (60.7)
Specialist 191 (9.7) 602 (8.1) 1385 (7.9)
Other/Unknown/
No ﬁll or visit
425 (21.7) 1943 (26.1) 5497 (31.4)
Patients with at least 1
specialist TG Rx ﬁll
246 (18.3) 636 (13.0) 1201 (11.3)
P.P. Toth et al. / Atherosclerosis 237 (2014) 790e797 793HbA1c levels, as shown in Table 3. Still, during follow-up, TG levels
remained higher than 150 mg/dL in all three cohorts, and sub-
stantial proportions of patients in each cohort had HDL-C levels
<30 mg/dL, representing residual risks for pancreatitis and CVD,
respectively.or ofﬁce visit during
follow-up, n (%)e
TG ¼ triglyceride.
a Medication initiation was assessed between index date and index date þ120
days.
b Discontinuation, switching, augmentation, and PDC were assessed over the
entire 12 month follow-up period among the subset of patients who had mono-
therapy with ﬁsh oils, ﬁbrates, or niacin.
c PDC ¼ Proportion of days covered.
d On index therapy ﬁll or closest ofﬁce visit. PCP¼ primary care physician (family/
general, internal medicine, geriatrics); “Specialist” includes American Board of
Clinical Lipidology-certiﬁed lipidologists and AMA-certiﬁed cardiologists, endocri-
nologists, and gastroenterologists. TG-related Rx ﬁlls include ﬁlls for ﬁbrates, ﬁsh
oils, or niacin.
e Among patients with a ﬁll or ofﬁce visit from a PCP around index date.3.5. Pancreatitis comparison at follow-up
Of the1964patients inCohortA, a total of 131patientswere found
to have acute pancreatitis events during follow-up (Table 4). Mean
age was 44e47 years, and patients were predominantly male. Pa-
tientswithpancreatitiswere likelier to havediabetes (52.7 vs. 36.3%),
hypertension (61.1 vs. 47.2%) and dyslipidemia (70.2 vs. 55.3%). In
addition, patients with pancreatitis were signiﬁcantly more likely,
relative to patients without the condition, to have liver disease (16%
versus 3.3%), alcohol abuse (21.4% versus 7.5%) and acute and chronic
pancreatitis (29.8% versus 2.3%) at baseline (all p < 0.001). Patients
with acute pancreatitis were found to have higher mean TG (3622
versus 2402 mg/dL) and total cholesterol (492 versus 383 mg/dL)
levels. Mean pancreatitis-related total costs at baseline, consisting
predominantly of medical costs, were signiﬁcantly greater for pa-
tients with pancreatitis relative to those without it ($4646 versus
$355, p<0.001). This trendpersisted at follow-upwithmean costs of
$16,694 among patients with pancreatitis.
Inamultivariable logistic regressionmodelamongpatientswithTG
levels 1,500, a 100 mg/dL increase in TG level on index date was
associated with a signiﬁcant 4% increase in the risk of an acute
pancreatitis event over follow-up (OR 1.04; 95% CI 1.03e1.05;
p < 0.0001). A similar multivariable logistic regression model was
created in a sample combining patients from Cohorts A, B, and C, and
using as the main predictors a set of 6 indicator variables based on TG
rangeson indexdate.HigherTGrangeswere typicallyassociatedwitha
higher riskofacutepancreatitis,withapronounced risk increase forTG
levels >2000mg/dL (OR 12.8; 95% CI 8.8e18.6; p < 0.0001; see Fig. 3).3.6. Healthcare resource utilization and costs at baseline and
follow-up
At baseline, approximately 10% of patients in all cohorts had 1
all-cause inpatient hospitalizations and 90% had physician ofﬁce
visits; the mean number of Rx ﬁlls was 27. Between 41 and 46% of
patients had physician ofﬁce visits with an ICD-9-CM diagnosis
code for dyslipidemia (272.xx), but the mean number of Rx ﬁlls for
TG-related medications (ﬁbrates, ﬁsh oils, niacin) was <2 across all
cohorts (Appendix Table A1). Utilization increased across all co-
horts during follow-up, in particular for inpatient hospitalizations
and Rx ﬁlls, although the number of mean TG medication ﬁlls was
still low (2e4 ﬁlls) (Appendix Table A2). Cohort A usually had the
highest utilization during both time periods.
“Monotherapy – Other” includes niacin, fish oils, and others
45.2 50.5
56.7
14.7
17.3
18.412.8
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Monotherapy - StaƟns
No RX claim
Fig. 2. Medication market segmentation around 6 months.
P.P. Toth et al. / Atherosclerosis 237 (2014) 790e797794All-cause costs were broadly similar in all three cohorts at
baseline (mean total medical and Rx costs $8305e$8850, of which
approximately $2600e2800 are Rx related), while disease-related
costs appeared highest in Cohort A ($1963; Appendix Table B1).
At follow-up, the distinction between Cohort A and Cohorts B/C
became more pronounced for both all-cause and disease-related
costs, and in particular for inpatient costs ($4025 vs. $3180 vs.
$2879, all-cause; Appendix Table B2).
Upon adjusting for baseline confounders, the presence of one or
more acute pancreatitis events at follow-up was associated with a
>300% increase in total all-cause costs (pseudo-OR 3.69; 95% CI
2.96e4.60; p < 0.0001), withmean costs among patients with acute
pancreatitis events of $31,993 vs. $11,259 among patients without
events (Table 4).Table 3
Laboratory results around index date versus 12 months follow-up.
Cohort A
TG1500
(n ¼ 1964)
Cohort B
750TG<1500
(n ¼ 7432)
Cohort C
500<TG<750
(n ¼ 17,500)
n/Mean %/SD n/Mean %/SD n/Mean %/SD
Baseline laboratory valuesa
Triglycerides, mean (SD) 2483 (1348) 975 (609) 589 (71)
LDL-C, mean (SD) 96 (50) 101 (39) 109 (39)
Total cholesterol, mean (SD) 390 (159) 263 (63) 235 (50)
HDL-C, mean (SD) 36 (14) 34 (11) 36 (10)
Patients with HDL-C
<30 mg/dL, n (%)
666 (35.2) 2614 (35.8) 4290 (25.0)
Hemoglobin A1c, mean (SD) 9.3 (2.7) 8.4 (2.5) 7.7 (2.3)
Followeup laboratory valuesa
Triglycerides, mean (SD) 772 (993) 424 (291) 316 (167)
LDL-C, mean (SD) 97 (41) 102 (38) 107 (38)
Total cholesterol, mean (SD) 234 (103) 209 (57) 203 (47)
HDL-C, mean (SD) 38 (14) 39 (11) 41 (12)
Patients with HDL-C
<30 mg/dL, n (%)
202 (24.2) 604 (20.0) 904 (13.4)
Hemoglobin A1c, mean (SD) 7.7 (2.0) 7.6 (1.9) 7.3 (1.8)
TG ¼ triglyceride; SD ¼ standard deviation; LDL-C ¼ low-density lipoprotein
cholesterol; HDL-C ¼ high-density lipoprotein cholesterol.
a Among subset of patients with available laboratory results.4. Discussion
The ﬁndings of this study represent new real-world informa-
tion on the clinical and economic outcomes of patients with
highly elevated TG levels. A notable number of patients with very
severe HTG (deﬁned as TG  1500 mg/dL) in the study population
experienced acute pancreatitis events, which substantially
increased their healthcare utilization and costs. At baseline, pa-
tients with higher TG levels had greater health care resource
utilization, including inpatient hospitalizations, and costs than
those with lower TG levels. During follow-up, healthcare utiliza-
tion and costs increased markedly across all cohorts. Episodes of
pancreatitis were associated with a threefold increase in total all-
cause costs among patients with TG  1500 mg/dL. One of the
reasons for this may be the need for costly diagnostic procedures
such as ultrasound and CT and MRI scans of the pancreas in these
patients.
While this patient population has not been studied extensively
and data on health care utilization and costs are scarce, the results
in this study are directionally consistent with the ﬁndings of earlier
assessments of this population [4,6,17,18]. As of now, however, this
appears to be the ﬁrst study to evaluate healthcare utilization and
costs for a large real-world population with highly elevated TG
across different severity levels.
A study by Christian et al. [4] investigated changes in clinical
events and healthcare utilization and costs for patients who had
severely elevated TG levels but whose TG levels dropped below
500 mg/dL at follow-up, within two large US-based healthcare
databases. The study reported that patients whose TG levels
remained 500 mg/dL had greater rates of pancreatitis, cardio-
vascular events, diabetes-related complications, and kidney disease
versus patients with lower TG levels. While our study did not assess
patients with TG < 500 mg/dL, our results were directionally
consistent with the ﬁndings by Christian et al. in that both studies
showed that higher TG levels were associated with greater disease
risk and costs. Underscoring the need for treatment, Christian et al.
concluded that at TG levels <500 mg/dL, there was a reduction in
the risk of clinical events as well as in costs and the use of
healthcare services.
Table 4
Comparison of patients with and without acute pancreatitis at follow-up.
Patients with acute pancreatitis
at follow-up (n ¼ 131)
Patients without acute pancreatitis
at follow-up (n ¼ 1833)
P e value
n/mean %/SD n/mean %/SD
Baseline demographics, n (%)
Female 37 (28.2) 346 (18.9) 0.0089
Age, mean (SD) 44 (8.4) 47 (8.8) 0.0025
Baseline comorbidities, n (%)
Quan-Charlson comorbidity score, mean (SD) 1.31 (1.6) 0.86 (1.4) 0.0018
Diabetes 69 (52.7) 665 (36.3) 0.0002
Renal disease 8 (6.1) 36 (1.9) 0.002
Liver disease 21 (16.0) 60 (3.3) <0.0001
Hypertension 80 (61.1) 865 (47.2) 0.0021
Obesity 18 (13.7) 141 (7.7) 0.0142
Alcohol abuse 28 (21.4) 138 (7.5) <0.0001
Hypothyroidism 16 (12.2) 107 (5.8) 0.0036
Dyslipidemia 92 (70.2) 1013 (55.3) 0.0009
Pancreatitis (acute or chronic) 39 (29.8) 42 (2.3) <0.0001
Mental health disorders 52 (39.7) 364 (19.9) <0.0001
Baseline lipid levels, mean (SD)b
Triglycerides 3622 (2075) 2402 (1242) <0.0001
LDL-C 97 (48) 96 (50) 0.9539
Total cholesterol 492 (240) 383 (150) <0.0001
HDL-C 38 (14) 36 (14) 0.1495
Health care costsa, USD mean/patient (SD)
Baseline all-cause total costs 15,938 (24,095) 8343 (22,037) 0.0006
Medical costs 13,020 (23,191) 5525 (20,123) 0.0004
Pharmacy costs 2917 (4070) 2818 (5925) 0.7946
Baseline pancreatitis-related total costs 4646 (11,127) 355 (5746) <0.0001
Medical costs 4646 (11,127) 355 (5731) <0.0001
Pharmacy costs 0.00 (0.00) 0.47 (20.25) N/A
Follow-up all-cause total costs 31,993 (31,956) 11,259 (22,306) <0.0001
Medical costs 26,980 (30,223) 7278 (20,454) <0.0001
Pharmacy costs 5013 (5874) 3981 (6554) 0.0558
Follow-up pancreatitis-related total costs 16,694 (26,065) 3 (98) <0.0001
Medical costs 16,667 (26,039) 0.00 (0.00) N/A
Pharmacy costs 26 (148) 3 (98) 0.0771
a Annualized costs including both plan and patient paid amounts. Pancreatitis-related costs include all medical claims with an ICD-9-CM code of interest (577.0x), and all
pharmacy claims for digestive enzymes.
b Among subset of patients with available laboratory results.
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that compared costs for patients whose TG levels decreased by 60%,
45%e59%, 30%e44%, 15%e29%, or 0%e14% over 5 years of follow-
up. Patients who reduced their TG levels by 60% had a mean
annualized cost reduction of $471 from baseline, while costs
increased for patients in all the other categories. While cost dif-
ferences between groups were most noticeable in the ﬁrst three
years, the differences were not statistically signiﬁcant.Fig. 3. Association between baseline TG level and risk of acute pancreatitOur results are also consistent with the ﬁndings of Gaudet et al.
[6], which used a large US claims database to conduct a 1:1
matched case versus control study, in which the cases were pa-
tients with chylomicronemia of varying etiology (2 diagnoses
with ICD-9-CM code 272.3) and the controls were free of the con-
dition. The study reported that the annual per patient medical costs
were greater by $809 for chylomicronemia cases without pancre-
atitis compared with the control patients ($8029 versus $7220,is over 12 months follow-up (sample combining Cohort A, B, and C).
P.P. Toth et al. / Atherosclerosis 237 (2014) 790e797796p < 0.01). The presence of pancreatitis was associated with higher
rates of inpatient hospitalizations, more severe clinical burden such
as abdominal pain and higher overall medical costs relative to
controls ($33,587 vs. $4402, p < 0.01).
In a study to describe the independent contribution of hyper-
triglyceridemia on healthcare costs using an observational cohort
drawn from the Kaiser Permanente health system, Nichols et al.
[17] concluded that 33%e38% greater medical costs per year were
attributable to severe hypertriglyceridemia independent of other
costly related conditions such as cardiovascular disease and
diabetes.
In our study, the majority of patients were not diagnosed with
hypertriglyceridemia. In addition, we found that ﬁbrates and ﬁsh
oils are underutilized for the treatment of these patients. The low
rates of drug utilization, switching, augmenting, and medication
adherence suggest that severe hypertriglyceridemia is undertreated
and that patients are not adequately counseled on the importance
and need for long-term adherence. Furthermore, the low rate of
utilization of specialists suggests a considerable need for greater
awareness of howsevere hypertriglyceridemia increases the risk for
cardiovascular and pancreatic disease. This treatment gap would
likely beneﬁt fromamoremultidisciplinary approach to treat severe
hypertriglyceridemia and reduce its adverse consequences.
Lipid proﬁles and HbA1c values differed across cohorts, but
consistently improved at 12 months from initial measurement. TG
and HDL-C remained suboptimal for a signiﬁcant percentage of
patients, especially among those with the most severe hyper-
triglyceridemia, implying potential residual cardiovascular and
pancreatitis risks. Acute pancreatitis occurred in a substantial
number of patients with very severe hypertriglyceridemia
(TG  1500 mg/dL). Among patients with acute pancreatitis, there
is a signiﬁcant prevalence of cardiovascular comorbidities. Acute
pancreatitis was also associated with a dramatic increase in total
all-cause costs by >300%.
Among other real-world implications for payers and providers,
these results suggest that healthcare utilization and costs scale
directly with the level of TG elevation. It is conceivable that with
the rising rates of obesity and diabetes and their links to cardio-
vascular events, the management of conditions such as hyper-
triglyceridemia, chylomicronemia, and pancreatitis would require
considerably greater healthcare resources and costs in the future.
Timely and appropriate treatment could impact both clinical and
economic outcomes. Patients with more severe hyper-
triglyceridemia require substantively more medical intervention
and pharmacotherapy. As a result, effective and timely treatment of
severe hypertriglyceridemia and the prevention of acute pancrea-
titis may result in substantial cost savings.
4.1. Limitations
A number of factors must be considered in the interpretation of
the ﬁndings reported here. This study relied on secondary data
from large commercial health plans across the US. While they may
be applicable to other commercial health plans, they may have
limited external validity to other types of patient populations such
as the Medicaid and Medicare programs in the US and government
sponsored health services in other countries. The secondary data
sourcewas a large administrative claims data repository; as a result,
no information was available on race and ethnicity nor on risk
factors capable of inﬂuencing outcomes such as family history,
smoking status, body mass index measures, diet and exercise and
educational and socioeconomic levels.
It is possible that the disease codes in the claims database used to
identify dyslipidemia and acute pancreatitis may not correspond
entirely to the truepresenceof these conditions since these codes areinitially enteredbyhealth care providers for thepurposeof insurance
billing. Utilization of over-the-counter medications, including most
ﬁsh oils and niacins, could not be assessed. Lastly, the study popu-
lation was deﬁned using a single observed TG level to maximize
capture. As a result, the sample could include patients with error in
measurementornon-fastingTG level; thevastmajorityof lab results,
however, may be assumed to be fasting based on clinical experience.
Furthermore, requiring at least 2 elevated TG levels is expected to
compromise sensitivity as testing occurs infrequently and treatment
initiation may have affected TG levels between measurements.
5. Conclusions
The ﬁndings of this study suggest that severe hyper-
triglyceridemia is undertreated. At current treatment levels
important residual pancreatitis risks may remain unattended,
especially among patients with the most severe hyper-
triglyceridemia (TG 1500mg/dL). Acute pancreatitis occurred in
a substantial number of patientswith severe HTG and is associated
with a signiﬁcant number of comorbidities and increased health
care utilization and cost burdens. There is a clear unmet need for
additional disease education targeting both providers and the
patient population as well as for the development of new treat-
ments for HTG. Additional research on the clinical and economic
outcomes associated with these conditions in larger populations
and over longer time horizons is also indicated.
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